Numbers That Speak for Themselves.
Nexus Clinical Network tracks the metrics that matter most to sponsors — enrollment velocity, data quality, protocol compliance, and study completion. Here's how we perform.
Enrollment Performance
Faster Enrollment. Fewer Delays.
Our pre-screened patient databases, community relationships, and proactive recruitment strategies consistently deliver enrollment rates that outpace industry benchmarks.
Across Phase II–IV studies, Nexus sites enroll patients at twice the rate of the industry average, driven by active patient registries and community outreach programs.
Our combined patient database includes over 100,000 pre-screened individuals across therapeutic areas, enabling rapid identification of eligible candidates at study startup.
From site initiation visit to first patient enrolled, Nexus sites average 14 days — well below the industry average of 30–45 days for comparable study types.
92% of Nexus studies meet their enrollment targets on or ahead of the agreed timeline, reducing sponsor costs and protecting study milestones.
Data Quality
Clean Data. First Time.
High-quality data reduces query burden, accelerates database lock, and protects your regulatory submission. Our coordinators are trained to get it right the first time.
95% of data entered by Nexus coordinators passes CRF review without requiring a query — reducing monitor burden and accelerating database lock.
Our network-wide query rate is under 2% per data point, compared to an industry average of 4–6%, reflecting rigorous coordinator training and proactive source data verification.
Outstanding queries are resolved within 48 hours on average, keeping data review cycles short and database lock timelines on track.
Nexus sites have received zero critical findings across all sponsor audits and regulatory inspections in the past 24 months, reflecting our commitment to GCP compliance.
Protocol Compliance
Rigorous Adherence. Every Visit.
Our protocol deviation rate is under 5% across all active studies — well below the industry average of 8–12% — driven by thorough staff training and proactive protocol review.
98% of scheduled study visits are completed as planned, minimizing missing data and protecting the integrity of your primary endpoints.
Our screen failure rate is under 20%, reflecting accurate pre-screening, thorough eligibility review, and strong investigator oversight during the screening process.
97% of enrolled patients complete their assigned study, reflecting strong patient engagement, coordinator support, and community trust built over years of research.
Industry Comparison
Nexus vs. Industry Benchmarks
How our key metrics compare to published industry averages for Phase II–IV clinical trials.
Industry benchmarks sourced from published clinical trial performance literature and CRO benchmarking reports. Nexus figures reflect network-wide averages across completed studies.
Ready to Put These Numbers to Work for Your Study?
Contact our business development team to discuss your protocol and how Nexus can deliver the performance your study demands.